Retatrutide, developed by Soma Pharmaceuticals , represents a promising development in metabolic management . This dual-action drug combines incretin receptor activity with gut-derived receptor agonist stimulation , indicating remarkable potential in trial data for weight reduction . Scientists believe Retatrutide may provide a new solution for ind